Immunogenicity of SARS‐CoV‐2 mRNA vaccine in solid organ transplant recipients

Abstract

Abstract Background It is currently not well described if a two‐dose regimen of a Covid‐19 vaccine is sufficient to elicit an immune response in solid organ transplant (SOT) recipients. Results A total of 80 SOT recipients completed a two‐dose regimen with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) messenger RNA vaccine. Only 35.0% (n = 28) were able to mount a positive IgG immune response 6 weeks after the second dose of vaccine. Conclusion This emphasizes that SOT recipients need continued use of personal protective measures. Future studies need to closely examine the cellular immune response in patients with compromised antibody response to Covid‐19 vaccination.